Australia - English - Department of Health (Therapeutic Goods Administration)

3dmorphic pty ltd - 15811 - training model, anatomical, - anatomical models to assist surgeons with pre operative planning. improve and simplify the performance of surgical interventions by acting as an aid or reference to elaborate a pre-operative surgical plan, to transfer the plan to surgery and to determine the correct sizing of the fixture(s) eventually required as part of the surgical procedure.

Australia - English - Department of Health (Therapeutic Goods Administration)

3dmorphic pty ltd - 47847 - orthopaedic implant/instrument adaptor - a device used to join a prosthesis to a surgical instrument or a surgical instrument to another instrument. to create an extension or to connect two devices where the interfaces of the devices are not compatible.

Australia - English - Department of Health (Therapeutic Goods Administration)

3dmorphic pty ltd - 38161 - spinal cage - a system including a device intended to be implanted into the space of an intervertebral disc that has been partially or totally removed during surgery in order to allow bone fusion between two contiguous vertebral bodies, typically in the treatment of degenerative disc disease (ddd). the interbody fusion cage is intended to maintain the height between vertebral bodies adjacent to the device and support loading during fusion and can be of several different geometric forms. the interbody fusion cage is implanted between the bones of the spine providing mechanical stability and sufficient space for therapeutic spinal bone fusion to occur. this process helps to relieve pressure on pinched nerves and prevents vertebral slipping. bone graft is typically used to help with osseointegration. the interbody fusion device may be made of metal, polymer, or other artificial or biological materials, or it may be a combination of these. fixation screws and devices associated with implantation are included with the device. i

Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - apomorphine hydrochloride hemihydrate, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium metabisulfite; sodium hydroxide; hydrochloric acid; water for injections - apomorphine wockhardt solution for injection or infusion is indicated to reduce the number and severity of ?off? phases in patients with parkinson?s disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. conventional therapy should be continued during ?on? phases.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - morphine sulfate pentahydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - morphine sulfate pentahydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - morphine sulfate pentahydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - morphine sulfate pentahydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - morphine sulfate pentahydrate, quantity: 100 mg - tablet, modified release - excipient ingredients: hyetellose; povidone; hypromellose; magnesium stearate; purified talc; titanium dioxide; iron oxide black; macrogol 400 - for the management of severe pain where other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - morphine sulfate pentahydrate, quantity: 60 mg - tablet, modified release - excipient ingredients: hyetellose; magnesium stearate; purified talc; lactose monohydrate; hypromellose; povidone; titanium dioxide; sunset yellow fcf aluminium lake; macrogol 400 - for the management of severe pain where other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. is not indicated as an as-needed (prn) analgesia.